<SEC-DOCUMENT>0000200406-19-000019.txt : 20190401
<SEC-HEADER>0000200406-19-000019.hdr.sgml : 20190401
<ACCEPTANCE-DATETIME>20190401171938
ACCESSION NUMBER:		0000200406-19-000019
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20190401
ITEM INFORMATION:		Termination of a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190401
DATE AS OF CHANGE:		20190401

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JOHNSON & JOHNSON
		CENTRAL INDEX KEY:			0000200406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221024240
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			1230

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03215
		FILM NUMBER:		19721869

	BUSINESS ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
		BUSINESS PHONE:		732-524-2455

	MAIL ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a201804018-kauris.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sDD056D51B0641F361235D96ADF3CD9BE"></a></div><div><div style="line-height:173%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WASHINGTON, DC 20549</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to Section 13 or 15(d) of the</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities Exchange Act of 1934</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of report (Date of earliest event reported):&#160;&#160;April 1, 2019</font></div><div style="line-height:120%;text-align:center;"><img src="a201810238kcizasfiled_image1.jpg" alt="a201810238kcizasfiled_image1.jpg" style="height:45px;width:180px;"></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;padding-bottom:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:36%;"></td><td style="width:35%;"></td><td style="width:29%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New Jersey</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I-3215</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22-1024240</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or Other Jurisdiction of Incorporation)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission File Number)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(IRS Employer Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;padding-top:20px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">One Johnson &amp; Johnson Plaza, New Brunswick, New Jersey&#160;08933</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of Principal Executive Offices) (Zip Code)</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registrant&#8217;s telephone number, including area code:&#160;&#160;732-524-0400</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company    </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div><br></div><div><div style="line-height:173%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:173%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.01</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Events.</font></div><div style="line-height:174%;padding-bottom:13px;padding-top:6px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 1, 2019, Johnson &amp; Johnson (the Company) announced that Ethicon, Inc. has completed the acquisition of Auris Health, Inc. for approximately $3.4 billion in cash. Additional contingent payments of up to $2.35 billion, in the aggregate, may be payable upon reaching certain predetermined milestones. With Auris Health&#8217;s robotic platform technology, currently used in diagnostic and therapeutic procedures in the lung, Johnson &amp; Johnson will advance its commitment to combatting lung cancer and expand its digital surgery portfolio across multiple surgical specialties. </font></div><div style="line-height:174%;padding-bottom:13px;padding-top:6px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company will discuss the transaction further during its next quarterly earnings call on April 16, 2019.</font></div><div style="line-height:174%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The related press release dated April 1, 2019 is attached as Exhibit 99.1 to this report.</font></div><div style="line-height:174%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:173%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Statements and Exhibits</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:173%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Exhibits</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:173%;padding-bottom:9px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit No.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div><div style="line-height:120%;padding-bottom:2px;text-align:left;padding-left:4px;text-indent:144px;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex991aurisacquisition.htm"><font style="font-family:inherit;font-size:10pt;">99.1</font></a><font style="font-family:inherit;font-size:10pt;color:#0000ff;"></font><font style="font-family:inherit;font-size:10pt;">Johnson &amp; Johnson Press Release dated April 1, 2019.</font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:173%;padding-bottom:22px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:47%;"></td><td style="width:7%;"></td><td style="width:33%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Johnson &amp; Johnson</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;(Registrant)</font></div><div style="padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="padding-bottom:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:&#160;&#160;April 1, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Renee A. Brutus</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Renee A. Brutus</font></div><div style="padding-bottom:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assistant Corporate Secretary</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:173%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:173%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:173%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:173%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991aurisacquisition.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sDAAECBABE9A0418E7450D9B07BDDAD10"></a></div><div><div style="line-height:173%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:173%;padding-bottom:16px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 99.1</font></div><div style="line-height:144%;padding-bottom:12px;text-align:center;"><img src="form8kex991templateimage1a01.jpg" alt="form8kex991templateimage1a01.jpg" style="height:49px;width:192px;"></div><div style="line-height:144%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FOR IMMEDIATE RELEASE</font></div><div style="line-height:120%;padding-bottom:21px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Global Media Relations:</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ernie Knewitz</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(732) 524-6623</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investor Relations:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Matt Stuckley</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(732) 524-2617</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Christopher DelOrefice</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(732) 524-2955</font></div></td></tr></table></div></div><div style="line-height:173%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:center;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;font-weight:bold;">Johnson &amp; Johnson Announces Completion of Acquisition of Auris Health, Inc. </font></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Auris will Enable Johnson &amp; Johnson to Deliver on the Promise of Digital Surgery </font></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">and Drive Better Outcomes for Patients </font></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NEW BRUNSWICK, NJ -</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">April 1, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;- Johnson &amp; Johnson (NYSE: JNJ) announced today that Ethicon, Inc., has completed the acquisition of Auris Health, Inc. for approximately $3.4 billion in cash. Additional contingent payments of up to $2.35 billion, in the aggregate, may be payable upon reaching certain predetermined milestones. With Auris Health&#8217;s robotic platform technology, currently used in diagnostic and therapeutic procedures in the lung, Johnson &amp; Johnson will advance its commitment to combatting lung cancer and expand its digital surgery portfolio across multiple surgical specialties. </font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;We are focused on building a connected, data-driven digital ecosystem that pairs our market-leading surgical solutions with advanced technologies to improve the patient experience,&#8221; said Ashley McEvoy, Executive Vice President, Worldwide Chairman, Medical Devices, Johnson &amp; Johnson. &#8220;The passionate team and differentiated innovation from Auris will help us amplify the power of digital surgery to address unmet clinical needs and lead a transformation in surgical care and lung cancer intervention.&#8221;</font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Auris technology complements robotic platform technologies currently in development in general surgery with Verb Surgical, through the Johnson &amp; Johnson collaboration with Verily, and in orthopaedics with the acquisition of Orthotaxy. Johnson &amp; Johnson aspires to bring disruptive innovation to the full continuum of procedures, including open, laparoscopic, robotic and endoluminal.</font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The company will discuss the transaction further during its next quarterly earnings call on April 16, 2019.</font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:173%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:173%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">About Johnson &amp; Johnson</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At Johnson &amp; Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.</font></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">###</font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the acquisition of Auris Health. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Ethicon, Inc., any of the other Johnson &amp; Johnson Medical Devices Companies and/or Johnson &amp; Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities of the acquisition may not be realized or may take longer to realize than expected; challenges inherent in product research and development, especially at an early stage of the development program, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new products; competition, including technological advances, new products and patents attained by competitors; challenges to patents; and changes to applicable laws and regulations, including tax laws and global health care reforms. In addition, there are risks and uncertainties related to the ability of the Johnson &amp; Johnson family of companies to successfully integrate the technology, operations and employees of Auris Health, as well as the ability to ensure continued development of Auris Health products. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson &amp; Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2018, including in the section captioned &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; and &#8220;Item 1A. Risk Factors,&#8221; and in the company&#8217;s most recently filed Quarterly Report on Form 10-Q, and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at </font><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">www.sec.gov</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">www.jnj.com</font><font style="font-family:inherit;font-size:10pt;">&#32;or on request from Johnson &amp; Johnson. Neither the Johnson &amp; Johnson Medical Devices Companies nor Johnson &amp; Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.</font></div><div style="line-height:173%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:173%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>a201810238kcizasfiled_image1.jpg
<TEXT>
begin 644 a201810238kcizasfiled_image1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  24DJ  @    $ !H!!0 !
M    /@   !L!!0 !    1@   "@! P !     @!$<C$! @ 0    3@
M  !@     0   &     !    4&%I;G0N3D54('8T+C P /_; $,  @$! 0$!
M @$! 0(" @("! ," @("!00$ P0&!08&!@4&!@8'"0@&!PD'!@8("P@)"@H*
M"@H&" L,"PH,"0H*"O_; $,! @(" @("!0,#!0H'!@<*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"O_  !$( "\
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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MM-M(Y-R->3[<[Y4>*),95V<*GO\ \ +OQGJ/P3\(ZA\1]7_M'Q%/X:L)=8U
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M;)'ZU^9?_!6#]GV[MI/BU9? 37HK/3?$7@6/Q7\8M&DM/,BCGL)U?3[F!O\
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M>]S<THTXT^;X5RIJ-^7WO>E+WM;*; ]*,#TH'2BNK0^?"C ]*** "C ]***
.."C SG%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>form8kex991templateimage1a01.jpg
<TEXT>
begin 644 form8kex991templateimage1a01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  24DJ  @    $ !H!!0 !
M    /@   !L!!0 !    1@   "@! P !     @!$<C$! @ 0    3@
M  !@     0   &     !    4&%I;G0N3D54('8T+C P /_; $,  @$! 0$!
M @$! 0(" @("! ," @("!00$ P0&!08&!@4&!@8'"0@&!PD'!@8("P@)"@H*
M"@H&" L,"PH,"0H*"O_; $,! @(" @("!0,#!0H'!@<*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"O_  !$( "\
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
M A$#$0 _ /WW()D4@# SD^E,+*9.5QC@'')ISNIY!P ,L37Q3^V;^WYXOT;2
M_BG:_ +7UTO3/A+I")XI\7+#%-)/K=R=MGI=FDR/#O\ -9//E=7V;Q'LW$LF
M5>O2PT>:1ZV1Y#F/$&,]AA(W^'WGM'FE&,?_  *4HQ7FS[:4@<E<4C$D9Z>E
M9/A6'6+;PSI\7B&^^U7R640O+E4V^;+L&Y]J],MVJ#Q_XXT3X=^#=6\=^)9S
M#8:/ID]]>R!<[(8D9V;_ +Y4UIS7AS'FJC*5?V,/>E>QL@%SL!7Y>O'7_"GQ
MJNWE<>N:^./^";_[8GQ[_:9\:7ES\2Y--DTO6?!5GXGL+"PM"IT(7&HZA;16
MC2X_?;[>UCEW-\V_S/X"@K['1P5.3SGK6=#$1Q%'GB>CGF28KA_,YX'%<OM(
M[\O?K_7W:$G2BC(')-&1ZUJ>4%%&1ZT9'K0 4$X&:,CUI,C&<T 1-(Q4-L8G
M/K2A1@JO8\&ODG]K?]NK5?"7B/QYX!^#^JK90?"_PQ_;/Q*\6B*.5M/::-WL
MM-M(Y-R->3[<[Y4>*),95V<*GO\ \ +OQGJ/P3\(ZA\1]7_M'Q%/X:L)=8U
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M;)'ZU^9?_!6#]GV[MI/BU9? 37HK/3?$7@6/Q7\8M&DM/,BCGL)U?3[F!O\
MEC/<-;W"O_?6S9^''S^+G-.I4PS=/^67_DQ^O^#N98/#Y]#"XEJ*E5H5.9_#
M^[G[T9?XHR?+WG&,>MSVSQ5_P4YN?%_[0/PY_9N_9>\(6VO3^,;B8W/BS5'D
M738H[2+S;N&WV;?M,JHK)O5O*27Y"7=)$3S#XM_M\?'CX@?LM?&?X$?'3]EK
M7]+\<6'PXO[B[?1K)[>QMK&YL[A'N&ENI4!6!TE3=$\OG;,Q?QI'UOQ%_8B^
M*'QJ^!7P#^/O[+OC/2?!GQ&^&WABU?15U6UQ8W45Q9Q+-;R^6CF, 9Y56R&=
M?X]Z]QHW[%7Q_P#&/P6^+5S\?_BCH6J_$OXI^!I_#D=QIFFO!I>CVJV]TEO;
MQ9S*Z>;=S2N[?.V_&/D%1RYC4G*,_P#[7EY?_2N8]&57P]RRC0JT84W*$E&<
M9RJ>VC4C7E[WNV@Z<J7+?SBTO>/CS]GG]KS6?V#?V5_A9JWP]\+VOB[7_'5Y
MH<?C?5M4#QP:/I\IDBL=/A6)O]:88+EE[(XEF=/WRH?JC]I/_@IAX@^%'[7W
MPZ^ GPU\!6.I^&]:\60Z)XO\2W;ML@NYEB=K6WV,/WL23Q2RNX9/WJI]_?LX
M3QA_P1W\:)^P-X*_9I^'7Q'TJR\9:)XTL?$7B'Q%J$<LT5U<1Q21-M^3<ZQ1
MO$D*LJ?);H#LSQV?[5'_  2KC^.&A_!GX=^#O'+:1HG@;Q!/?>+-0N9I5U#5
MDG DNIUEBQ_I<TP9G=MH_?.W\.PX4Z&;4,/RP_N?_;1_S9[&9YIX6YUGL<7C
M)<W//%QG+WK\O+^YJ<NGPOW805O=MS:K67X(_P#!4'6?BK^VSXQ^"^O^$-+T
M?X<Z/X"F\2Z%XFN;EEN+RVBG@C^UL=VQ;>597D3*AMB*_P#'A<KX+_\ !8*U
M^)?A?Q\EU\$]4A\6>$=1U">VT&>&2U2+1(X_/M]0OYYEVV:^21O7YW9@?*1^
MVIXR_P""8>L^,_\ @H!_PO\ O/%MA:?#>;P79Z-J7A>RA9)KU;:6.5+5\*%6
MUWPP,X#'>B/"4V.Q,W[-O_!-;Q;X.^./Q=^*WQY\86.JP_$C3[K29+?3;NX=
MKRSGN)F$TXE4+#*EN\5ND4>]$2'[YSQT1_M6_+_>E_P#P\0O"CZI.OR^][&A
M*$8N6E164XO3WG)<SG9Q^SRO5\O%^'?^"F?[7VA? CP9^U;\0?V?](N_ WB"
MWO-2U<^&;>ZFGTZR6Z2..-WWNJR^3YMSYTFR)\>3^Z8;WWM)_P""FWQ8\'_M
M=>(O@U^T+\'M.\*^&[/X=-XITVWM[][W5D5)51(9]C>4\TF=OE1;_G95WO6!
M\&O^";?[;W@7P>O['?C3]H_PQ>? RWU4RH8-(D;7;VP^T"=K!V8>7"CMN#OO
ME?YVVX7"#TCXC_\ !..Z^*'_  4CT;]K[Q=XFLYO"NA^$[:VBT ._GW>HP7$
MDL32KLV&!&:*9?GSYT*';WJ:4<SY(R][[/Q<O_;W_;IOBZGAC#&XBG4C3E2E
M&M*$J?M;\O-&5"'O:1J6YHRNI):7>YH?\$VOVV/B?^U]I?Q*?XT^!-*\+ZAX
M(\:W&D-::?.S+%&B@LDKL[*[JP<,Z[4; ^0<Y]#\2_MS_LU:+KGAKP[H_P 1
M=/UX>*/$@T&VN_#EW%?06E\T<CQQ7#1.?)W^4Z*3_$,5XG^S#_P37^*GPH_:
M%^*_B+XF?%FSOOASXW\3ZMJUEX2TGSHFU!M0$JNM\P5?DABFE18E9T=W6;Y'
M1*K>)?\ @C7\/EOO!(^'OQ7\46VF>"?$UM>Z+I5]>6O_ !+K19O-EB@NH[7[
M8QW<HLMPRJWS=N=Z=3,HX>-X^]_]M_D>%F>$\.,3Q#5G'$>SHRC"48TXR<8M
MTO>C>7O7C4MW5F_>NK'RC\2SKLW[#_[;IO\ S5U\?',/J.X_O18'4[0Q?]LO
M+\S9_L5]/-_P5$22'X._ ;]F_P *6_B'7O'"6.GW/B345D&E:4T=K#-=+\NP
MW<\43'=$CH$=E5G#?)7GW_!0[]D"W^']]XST#]F/QCJ$5YX\^&^I:G\5-/U^
M\N-32XL],1)+6[\VXF+P7+RA;9/O)L>5E1?)KI-+_8:\;?M*_P#!/[]G/XA_
M /QM9>#_ (@_#OPOIFK^%;ZXLO\ 19I);6%IDE"*W$KJC.VU]WS;D??7GPIX
MZG6E"G\48_\ M_-[O_;LOO/T#%8O@O-,FPE;'SO3J59M<W-'V<I8:G3BZD8J
M5X^UH^ZHO^'9R5M'MW7_  4$_:"UJP\>? +XT?LF:[;>+1X;O[W1+?P] 8[9
M[)9)8':2XNW2)UB!MW-Q$[+)Y_RHK(4KY8_9@_:L\0?L"_\ !//P[\;OA?X7
MMO&'C'6X,ZW_ &KA+7P[H46KWEO;P':RN[7%T]TR?WW>9_N0U]Y?!W]D[]HK
M5)?%7Q7_ &L_B9H.L^/-?\)-X<TBV\-V,L&F:+9G>[JGF'=,\LK([NR](44=
M.?%D_P"".'C+1/\ @F9J'[(_AWQUI$GCO6=6L]1U;7+UIOL3/%<B1;9'V^:L
M2)NV?)]]W?8N\XJMA\QD_:Q^+EER_P W]TY<EX@\/<-A9Y;BO9QI5,3AG4C#
MVDJ<H*%15+2E[ZA!RB^\I:>]$[K]MG_@I?XR_9T^,'@3X:_"WP'8ZM8ZAXNT
MK2O'&LWSL8=.-[\Z6D6QU_THVX:;^)41HMR_ODJ3P)_P4S\0>-_^"A/_  S-
M:>#+"U\ 7'A.\U/3?$UU*PNKV2VFDAEN%R^U+7=!.B_(=^Q90^Q\53_:D_X)
M:>(?C5^SY\._@CX.^),5IJ6A^/H?$?C3Q;>*4O=3G:*;[5=1E%XN&>1=BG:B
M(JH-J(@J'XT?\$IM3^)/[7_A'XI>&/&>GZ%\.-&^'4/A36O#-E&RW-W9Q2RO
M]D0[=J6\B2+&[;M^P.@'S[TZ:O\ :KJ\R^'FC_P3Y[ _\0L>5TZ-=Q57V=>+
ME[_Q1UI5+=92>D(_"HZ2U]X?\$/^"NND?&3Q?\0O FF?"?5[K7=&U5+GP'I%
MO"UO_:FB-;HT>IW$\OR00<&9I&Q^ZN($1)9'"/RO@O\ X*;?MDZU^SOX?_;"
MO?@/H6I^!=5U+6)M2M_#UO>7%S8Z=93+" S[L^8_EWC^:\20KY,:/LW[U]&_
M9^_X)X>-O G[:_CK]JGXD>+]-NK36-%N]$T>PT]I2T]G-=K+$)U9%2!;>WBM
M[58HBZ.(O,.QCLKSCX;?\$R/VV_A=X4UK]CKPU^TKX<3X#ZO>W!=VTJ5]>M]
M/G?=/8Q97RD\U6=&F+MS(SHB?<J?^%:WO\WVOAY?^W3K3\+/:55A84XO]Q)^
MUE4=U[.4:\8."^)3Y)1TNW=7Z+H4_P""JGQ,\,_M<Z!\,OC#\)=,\(_#[Q'X
M!O?$MK?WM^9=4MK6&.:19I_*8Q0AE@;]TN]AN7YPWR5VW_!/#]N[XJ?M;?$_
MXM> _BE\+[3PO)X%UFRCTNRAF+7"6]P)]L=UAW3SE\G+;=H^;;M!3)S_ ([_
M /!,Y?CA^V_\-?V@+W7K*T\%>!_#2V5WX>C202W4T$S2P1<?)Y&64ON_YXA=
MIWY2/X"_\$_?C;\)OV[/B)\=V^,UM!X!\8:W!K+>'])$T5YJ%U#'*L4-T^T;
M;='GD?:CMYI1-_R9CK2E_:D,3[WO1YO_ "7E_P#DC@S"7AIC.&ZBPT8TL5+#
M1EK[2T:L:_PQ^*\YTM^;W=%9J[/LD<BB@<"BO:/Q@AVY8.%  ':OSY\9^-;/
MXK_&_P#:&_8IFT;4YO'WQ%\8Z;8I''83>5:>%?[,LEDO6N-GE(BQ?;2BEOFF
ME5/X^/T&9RIVEN@Y--,49?[1$BAR.N.M<]>A[;EBV>_D&=T\DG5G*GS2E&/+
M[W+RRC.,XN7NRYHWCK'W;_S*Q#I&EV>CZ9;Z586J0PV\"1111\*BJ,*HJ]@>
ME SCFBN@\"<W.3;W88'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%!Z4
M ?G_ /&KXJ2ZC^U9^T#^S%::7J-QX_\ B/X<T30O ,<>E2RQ)I,EG*D]Z\JK
MLB@MYKN[E?>Z;]FQ-S\5]O?#?P)H7PR\ Z+\//#4.RPT/3(+&RC_ +D44:QJ
M/^^5K:$"F?SV09 X/>G2?*=YZ#K7+1HNG.3<OZW/H,ZSVGF>&HTJ5+V<8Q@I
M>]S<THTXT^;X5RIJ-^7WO>E+WM;*; ]*,#TH'2BNK0^?"C ]*** "C ]***
.."C SG%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
